Cargando…

Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis

About 20–40% of cancer patients develop brain metastases, causing significant morbidity and mortality. Stereotactic radiation treatment is an established option that delivers high dose radiation to the target while sparing the surrounding normal tissue. However, up to 20% of metastatic brain tumours...

Descripción completa

Detalles Bibliográficos
Autores principales: Karami, Elham, Soliman, Hany, Ruschin, Mark, Sahgal, Arjun, Myrehaug, Sten, Tseng, Chia-Lin, Czarnota, Gregory J., Jabehdar-Maralani, Pejman, Chugh, Brige, Lau, Angus, Stanisz, Greg J., Sadeghi-Naini, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934477/
https://www.ncbi.nlm.nih.gov/pubmed/31882597
http://dx.doi.org/10.1038/s41598-019-56185-5
_version_ 1783483391218286592
author Karami, Elham
Soliman, Hany
Ruschin, Mark
Sahgal, Arjun
Myrehaug, Sten
Tseng, Chia-Lin
Czarnota, Gregory J.
Jabehdar-Maralani, Pejman
Chugh, Brige
Lau, Angus
Stanisz, Greg J.
Sadeghi-Naini, Ali
author_facet Karami, Elham
Soliman, Hany
Ruschin, Mark
Sahgal, Arjun
Myrehaug, Sten
Tseng, Chia-Lin
Czarnota, Gregory J.
Jabehdar-Maralani, Pejman
Chugh, Brige
Lau, Angus
Stanisz, Greg J.
Sadeghi-Naini, Ali
author_sort Karami, Elham
collection PubMed
description About 20–40% of cancer patients develop brain metastases, causing significant morbidity and mortality. Stereotactic radiation treatment is an established option that delivers high dose radiation to the target while sparing the surrounding normal tissue. However, up to 20% of metastatic brain tumours progress despite stereotactic treatment, and it can take months before it is evident on follow-up imaging. An early predictor of radiation therapy outcome in terms of tumour local failure (LF) is crucial, and can facilitate treatment adjustments or allow for early salvage treatment. In this study, an MR-based radiomics framework was proposed to derive and investigate quantitative MRI (qMRI) biomarkers for the outcome of LF in brain metastasis patients treated with hypo-fractionated stereotactic radiation therapy (SRT). The qMRI biomarkers were constructed through a multi-step feature extraction/reduction/selection framework using the conventional MR imaging data acquired from 100 patients (133 lesions), and were applied in conjunction with machine learning techniques for outcome prediction and risk assessment. The results indicated that the majority of the features in the optimal qMRI biomarkers characterize the heterogeneity in the surrounding regions of tumour including edema and tumour/lesion margins. The optimal qMRI biomarker consisted of five features that predict the outcome of LF with an area under the curve (AUC) of 0.79, and a cross-validated sensitivity and specificity of 81% and 79%, respectively. The Kaplan-Meier analyses showed a statistically significant difference in local control (p-value < 0.0001) and overall survival (p = 0.01). Findings from this study are a step towards using qMRI for early prediction of local failure in brain metastasis patients treated with SRT. This may facilitate early adjustments in treatment, such as surgical resection or salvage radiation, that can potentially improve treatment outcomes. Investigations on larger cohorts of patients are, however, required for further validation of the technique.
format Online
Article
Text
id pubmed-6934477
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69344772019-12-29 Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis Karami, Elham Soliman, Hany Ruschin, Mark Sahgal, Arjun Myrehaug, Sten Tseng, Chia-Lin Czarnota, Gregory J. Jabehdar-Maralani, Pejman Chugh, Brige Lau, Angus Stanisz, Greg J. Sadeghi-Naini, Ali Sci Rep Article About 20–40% of cancer patients develop brain metastases, causing significant morbidity and mortality. Stereotactic radiation treatment is an established option that delivers high dose radiation to the target while sparing the surrounding normal tissue. However, up to 20% of metastatic brain tumours progress despite stereotactic treatment, and it can take months before it is evident on follow-up imaging. An early predictor of radiation therapy outcome in terms of tumour local failure (LF) is crucial, and can facilitate treatment adjustments or allow for early salvage treatment. In this study, an MR-based radiomics framework was proposed to derive and investigate quantitative MRI (qMRI) biomarkers for the outcome of LF in brain metastasis patients treated with hypo-fractionated stereotactic radiation therapy (SRT). The qMRI biomarkers were constructed through a multi-step feature extraction/reduction/selection framework using the conventional MR imaging data acquired from 100 patients (133 lesions), and were applied in conjunction with machine learning techniques for outcome prediction and risk assessment. The results indicated that the majority of the features in the optimal qMRI biomarkers characterize the heterogeneity in the surrounding regions of tumour including edema and tumour/lesion margins. The optimal qMRI biomarker consisted of five features that predict the outcome of LF with an area under the curve (AUC) of 0.79, and a cross-validated sensitivity and specificity of 81% and 79%, respectively. The Kaplan-Meier analyses showed a statistically significant difference in local control (p-value < 0.0001) and overall survival (p = 0.01). Findings from this study are a step towards using qMRI for early prediction of local failure in brain metastasis patients treated with SRT. This may facilitate early adjustments in treatment, such as surgical resection or salvage radiation, that can potentially improve treatment outcomes. Investigations on larger cohorts of patients are, however, required for further validation of the technique. Nature Publishing Group UK 2019-12-27 /pmc/articles/PMC6934477/ /pubmed/31882597 http://dx.doi.org/10.1038/s41598-019-56185-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Karami, Elham
Soliman, Hany
Ruschin, Mark
Sahgal, Arjun
Myrehaug, Sten
Tseng, Chia-Lin
Czarnota, Gregory J.
Jabehdar-Maralani, Pejman
Chugh, Brige
Lau, Angus
Stanisz, Greg J.
Sadeghi-Naini, Ali
Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis
title Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis
title_full Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis
title_fullStr Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis
title_full_unstemmed Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis
title_short Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis
title_sort quantitative mri biomarkers of stereotactic radiotherapy outcome in brain metastasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934477/
https://www.ncbi.nlm.nih.gov/pubmed/31882597
http://dx.doi.org/10.1038/s41598-019-56185-5
work_keys_str_mv AT karamielham quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT solimanhany quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT ruschinmark quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT sahgalarjun quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT myrehaugsten quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT tsengchialin quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT czarnotagregoryj quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT jabehdarmaralanipejman quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT chughbrige quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT lauangus quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT staniszgregj quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis
AT sadeghinainiali quantitativemribiomarkersofstereotacticradiotherapyoutcomeinbrainmetastasis